A Phase I, Randomized, Double-blind, Placebo-controlled, Multi-centre, Ascending-dose Trial to Evaluate the Safety, Tolerability and Immunogenicity of Vaccine FP-02.2 in HBeAg-negative Hepatitis B Patients as an add-on Treatment to Entecavir or Tenofovir.

Trial Profile

A Phase I, Randomized, Double-blind, Placebo-controlled, Multi-centre, Ascending-dose Trial to Evaluate the Safety, Tolerability and Immunogenicity of Vaccine FP-02.2 in HBeAg-negative Hepatitis B Patients as an add-on Treatment to Entecavir or Tenofovir.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs FP 02.2 (Primary) ; IC 31
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Sponsors Altimmune; Eli Lilly
  • Most Recent Events

    • 27 Mar 2018 According to an Altimmune media release, the company is evaluating the data and will provide the results after review.
    • 27 Mar 2018 Results published in an Altimmune Media Release
    • 19 Mar 2018 Planned End Date changed from 1 Oct 2018 to 29 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top